OBJECTIVE: The relatively modest benefit of vasomotor symptom relief in clinical trials of isoflavones may reflect once-daily dosing and low percentages of participants who are able to metabolize daidzein into equol, a potentially more biologically active isoflavone. This pilot study examined whether symptom reduction was greater with more frequent administration and with higher daily doses. In addition, we explored possible effect modification by equol producer status. METHODS: We randomized 130 perimenopausal (no menses in the past 3 mo) and postmenopausal (≥12 mo of amenorrhea) women with a mean of five or more moderate/severe hot flashes per day to treatment arms with varying total daily isoflavone doses and dosing frequency, separately for equol producers and nonproducers. Participants recorded the daily frequency and severity of hot flashes. Analyses compared mean daily hot flash intensity scores (sum of hot flashes weighted by severity) by total daily dose and by dosing frequency. Dose- and frequency-related differences were also compared for equol producers and nonproducers. RESULTS:Hot flash intensity scores were lowest in women randomized to the highest total daily dose (100-200 mg) and in women randomized to the highest dosing frequency (twice daily to thrice daily), with greater benefits on nighttime scores than on daytime scores. Dose- and frequency-related differences were somewhat larger in equol producers than in nonproducers. CONCLUSIONS: These results suggest that a twice-daily to thrice-daily dosing frequency may improve the benefit of isoflavones for vasomotor symptom relief, particularly in equol producers and for nighttime symptoms. Larger studies are needed to confirm these findings.
RCT Entities:
OBJECTIVE: The relatively modest benefit of vasomotor symptom relief in clinical trials of isoflavones may reflect once-daily dosing and low percentages of participants who are able to metabolize daidzein into equol, a potentially more biologically active isoflavone. This pilot study examined whether symptom reduction was greater with more frequent administration and with higher daily doses. In addition, we explored possible effect modification by equol producer status. METHODS: We randomized 130 perimenopausal (no menses in the past 3 mo) and postmenopausal (≥12 mo of amenorrhea) women with a mean of five or more moderate/severe hot flashes per day to treatment arms with varying total daily isoflavone doses and dosing frequency, separately for equol producers and nonproducers. Participants recorded the daily frequency and severity of hot flashes. Analyses compared mean daily hot flash intensity scores (sum of hot flashes weighted by severity) by total daily dose and by dosing frequency. Dose- and frequency-related differences were also compared for equol producers and nonproducers. RESULTS:Hot flash intensity scores were lowest in women randomized to the highest total daily dose (100-200 mg) and in women randomized to the highest dosing frequency (twice daily to thrice daily), with greater benefits on nighttime scores than on daytime scores. Dose- and frequency-related differences were somewhat larger in equol producers than in nonproducers. CONCLUSIONS: These results suggest that a twice-daily to thrice-daily dosing frequency may improve the benefit of isoflavones for vasomotor symptom relief, particularly in equol producers and for nighttime symptoms. Larger studies are needed to confirm these findings.
Authors: Katherine M Newton; Diana S M Buist; Nora L Keenan; Lynda A Anderson; Andrea Z LaCroix Journal: Obstet Gynecol Date: 2002-07 Impact factor: 7.661
Authors: Stephen Hulley; Curt Furberg; Elizabeth Barrett-Connor; Jane Cauley; Deborah Grady; William Haskell; Robert Knopp; Maureen Lowery; Suzanne Satterfield; Helmut Schrott; Eric Vittinghoff; Donald Hunninghake Journal: JAMA Date: 2002-07-03 Impact factor: 56.272
Authors: Kenneth D R Setchell; Marian S Faughnan; Tony Avades; Linda Zimmer-Nechemias; Nadine M Brown; Brian E Wolfe; Wayne T Brashear; Panjak Desai; Mark F Oldfield; Nigel P Botting; Aedin Cassidy Journal: Am J Clin Nutr Date: 2003-02 Impact factor: 7.045
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Bruce Ettinger; Sharon M Wang; R Scott Leslie; Bimal V Patel; Michael J Boulware; Mark E Mann; Michael McBride Journal: Menopause Date: 2012-06 Impact factor: 3.310
Authors: Mohammed M Alshehri; Javad Sharifi-Rad; Jesús Herrera-Bravo; Evelyn L Jara; Luis A Salazar; Dorota Kregiel; Yadav Uprety; Muhammad Akram; Mehwish Iqbal; Miquel Martorell; Margalida Torrens-Mas; Daniel Gabriel Pons; Sevgi Durna Daştan; Natália Cruz-Martins; Fethi Ahmet Ozdemir; Manoj Kumar; William C Cho Journal: Oxid Med Cell Longev Date: 2021-09-09 Impact factor: 6.543
Authors: Mercedes Y Lacourt-Ventura; Brayan Vilanova-Cuevas; Delmarie Rivera-Rodríguez; Raysa Rosario-Acevedo; Christine Miranda; Gerónimo Maldonado-Martínez; Johanna Maysonet; Darlene Vargas; Yelitza Ruiz; Robert Hunter-Mellado; Luis A Cubano; Suranganie Dharmawardhane; Johanna W Lampe; Abel Baerga-Ortiz; Filipa Godoy-Vitorino; Michelle M Martínez-Montemayor Journal: Int J Environ Res Public Health Date: 2021-08-04 Impact factor: 3.390